🔗 Share this article

American leader President Trump has announced agreements intended to reduce the price of widely-used obesity medications, as pharmaceutical prices become a focus in his administration's messaging about accessibility.

Important Arrangements with Drug Manufacturers

Making remarks alongside pharmaceutical executives at the White House, Trump unveiled arrangements with Eli Lilly and Novo Nordisk. Consumers are set to pay between $245 and $350 per month for weight-loss treatments like Wegovy and Zepbound.

Many GLP-1 drugs, used to treat type 2 diabetes and obesity, cost more than $1,000 per month without insurance or savings.

Enhanced Access to Government Health Programs

The arrangements will expand Eli Lilly's and the manufacturer's access to Medicare and Medicaid, the federal healthcare plans for older and economically disadvantaged individuals.

Eli Lilly also announced in a release it would be exempt from import duties for 36 months as included in the arrangement with the Trump administration.

Pricing Information

Roughly 10% of federal health program beneficiaries will be able for expanded access to GLP-1 drugs, and will have to pay only $50, as stated by top government representatives.

Those enrolled in Medicaid will see a staggered beginning based on when individual states opt in to join.

Government-Run Portal Roll-out

The weight-loss drugs will be available at reduced rates on the consumer-direct TrumpRx, a publicly managed site set to go live by the start of the year.

On the government website, Wegovy and Eli Lilly's medication will begin at $350 per month typically, and fall to $250 over a couple of years. The Medicare costs of Novo Nordisk's diabetes drug, Wegovy, Eli Lilly's treatment, and Zepbound will be $245.

More Drug Choices

In addition to Novo Nordisk's Wegovy, Eli Lilly's obesity pill, the experimental drug, will be available for $149 for the lowest dose, the manufacturer said in a statement. The company's weight-loss medication will cost $299 for a initial amount.

The prices are subject to regulatory agency clearance of the drugs.

Insurance Issues

Glucagon-like peptide-1 treatments are commonly not covered by commercial insurers. Federal law forbids the federal program from paying for the medications when prescribed for weight loss, though they usually are included when employed against type 2 diabetes and circulatory issues. Only thirteen states offer insurance under the state-federal plan for slimming reasons.

Health Secretary's Statement

The top health official the administration official, making remarks at the White House, said the agreements were products of an extended period of discussions with Eli Lilly and the drug manufacturer. He described excess weight "the number one driver of long-term illness" in the US.

"This will be a lifesaver to patients," the Health Secretary stated.

"This is not a cure-all, it's not a easy answer," he added, stressing the value of dietary changes and physical exercise.

History of Pharmaceutical Price Efforts

Starting in summer, the President has been urging pharmaceutical firms to lower drug prices. He sent letters to seventeen pharmaceutical firms in the warmer months, allowing them two months to answer to his demands for reduced rates.

Pfizer was the primary major medication manufacturer to reach a agreement with Trump, cutting costs for certain medicines by nearly eighty-five percent on the TrumpRx. Pfizer additionally agreed to reduce treatment rates for Medicaid.

The British-Swedish firm and EMD Serono have likewise reached agreements with the federal leadership in the past few weeks.